Galidesivir

Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM[1][2][3].

Product Specifications

CAS Number

[249503-25-1]

Product Name Alternative

BCX4430; Immucillin-A

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

DNA/RNA Synthesis; Filovirus; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/BCX4430-freebase.html

Purity

99.29

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O

Molecular Formula

C11H15N5O3

Molecular Weight

265.27

Precautions

H302, H315, H319

References & Citations

[1]Elfiky AA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278 against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) : A molecular docking study. Life Sci. 2020 Mar 25:117592.|[2]Taylor R, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9 (3) :220-226.|[3]Warren TK, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508 (7496) :402-405.|[4]Julander JG, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014;58 (11) :6607-6614.